Clinical Trials Logo

Multiple Myeloma clinical trials

View clinical trials related to Multiple Myeloma.

Filter by:

NCT ID: NCT06308822 Active, not recruiting - Clinical trials for Refractory Multiple Myeloma

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

Start date: June 19, 2018
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial tests how well JNJ-42756493 (erdafitinib) works in treating patients with tumors that have more copies of the FGFR gene than is normal (amplification). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals cancer cells to multiply.

NCT ID: NCT06304636 Recruiting - Clinical trials for Refractory Multiple Myeloma

Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma

DC15-MM-01
Start date: March 1, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase I dose-escalation study to evaluate the safety, tolerability and preliminary efficacy of an autologous BCMA-targeting RNA-engineered CAR T-cell therapy in patients with Relapsed/Refractory Multiple Myeloma. The cell product is referred to as Descartes-15

NCT ID: NCT06303167 Active, not recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Start date: August 6, 2015
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial evaluates the effectiveness of osimertinib (AZD9291) in treating patients with cancer that has certain genetic changes called EGFR mutations. Osimertinib is in a class of medications called kinase inhibitors. It works by blocking the action of mutant forms of the EGFR protein, which play a key role in tumor cell growth. Osimertinib may cause tumor cell death and inhibit tumor growth in EGFR-overexpressing tumor cells, thereby stopping or slowing the spread of tumor cells.

NCT ID: NCT06302699 Recruiting - Multiple Myeloma Clinical Trials

Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma

Start date: May 1, 2023
Phase:
Study type: Observational

The presence of minimal residual disease (MRD) is an important prognostic factor for multiple myeloma, while copy number variation (CNV) is a widely accepted biomarker used for multiple myeloma (MM). Detecting MRD and monitoring clonal evolution by monitoring CNV using low-pass whole genome sequencing is promising due to its high analytical sensitivity. To evaluate the correlation between MRD detected by flow cytometry and low-pass whole genome sequencing, nearly 200 samples were collected for this study. We applied ultrasensitive chromosomal aberrations detection to detect CNV for each patient. The follow-up samples were then collected and sequencing used the same method.

NCT ID: NCT06298266 Not yet recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma

Start date: March 29, 2024
Phase: Early Phase 1
Study type: Interventional

To evaluate the safety and tolerability of anti-GPRC5D-CD19 CAR-T cells infusion in subjects with relapsed and refractory multiple myeloma

NCT ID: NCT06297226 Not yet recruiting - Multiple Myeloma Clinical Trials

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

QUINTESSENTIAL
Start date: April 15, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma.

NCT ID: NCT06296368 Not yet recruiting - Multiple Myeloma Clinical Trials

DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics

DISCOVERY
Start date: April 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether a novel decision support tool called PRIME (Preference Reporting to Improve Management and Experience), which combines values-elicitation with tailored feedback to patients and providers, improves patient-reported values-concordance of initial treatment decisions compared to usual care.

NCT ID: NCT06296121 Recruiting - Multiple Myeloma Clinical Trials

A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma

DARVIVA
Start date: December 21, 2023
Phase: Phase 3
Study type: Interventional

The aim of this study is to confirm the comparability of the efficacy and safety profiles of BCD-264 and Darzalex as monotherapy for relapsed and refractory multiple myeloma in subjects previously treated with proteasome inhibitors and immunomodulatory drugs, and who had disease progression on prior therapy.

NCT ID: NCT06286241 Not yet recruiting - Multiple Myeloma Clinical Trials

Comparison of the Complications in Multiple Myeloma Patients Who Received Autologous Stem Cell Transplantation Between in HEPA-filtered Room and Non-HEPA-filtered Room

Step down ward
Start date: March 25, 2024
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to comparison of the complications in multiple myeloma patients who received autologous stem cell transplantation between in HEPA-filtered room and non-HEPA-filtered room. The main questions it aims to answer are: - The incidence of febrile neutropenia, infection, and duration of hospital stay - 2-year progression free survival Participants will be collected the data of baseline diagnosis, treatment, treatment results and complications during admission and follow-up visits from hospital medical record.

NCT ID: NCT06286228 Not yet recruiting - Multiple Myeloma Clinical Trials

Registry of Haploidentical Hematopoietic Stem Cell Transplantation in Adult With Hematologic Disease

Haplo
Start date: April 1, 2024
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to register hematologic patients with haploidentical hematopoietic stem cell transplantation (haploHSCT). The main questions it aims to answer are: - 1-year progression free survival rate - 1-year overall survival rate - Graft-versus-host free relapsed free survival at 30-day, 100-day, 180-day and 1-year - Chronic Graft-versus-host free relapsed free survival at 180-day and 1-year - Rate of Neutrophil and platelet engraftment - Efficacy of donor specific antibody desensitization - Relapsed rate - Primary and late graft failure - Safety and complication of haploHSCT - Complication of viral, bacterial, and fungal infection - Viral reactivation - Comparison outcomes between matched sibling donor (MSD) HSCT and matched unrelated donor (MUD) HSCT - Comparison cost-effectiveness of treatment between matched sibling donor (MSD) HSCT and matched unrelated donor (MUD) HSCT Participants will be collected the data of baseline diagnosis, treatment, treatment results of all admission and follow-up visits from hospital medical record.